The global Cell and Gene Therapy Market size was USD 1,180.0 Million in 2019 and is expected to reach USD 6,570.0 Million by 2027 growing at a CAGR of 19.8% during the forecast period, according to a new report by Emergen Research.
The global Cell and Gene Therapy Market size was USD 1,180.0 Million in 2019 and is expected to reach USD 6,570.0 Million by 2027 growing at a CAGR of 19.8% during the forecast period, according to a new report by Emergen Research. Continuing advances in cell and gene therapy (CGT) are transforming how biopharma companies develop and commercialize medicines. In particular, the ability to target and modulate the activity of specific cells in the human body has created opportunities to develop treatments for a range of currently incurable diseases.
The cell and gene therapy market is still in its early stages, with only a handful of approved products on the market. However, the potential for this technology is enormous, and the market is expected to grow rapidly in the coming years.
There are several key drivers of this growth, including the increasing number of clinical trials underway, the commercial success of some early products, and the growing investment by biopharma companies in CGT research and development.
Request Free Sample Copy (To Understand the Complete Structure of this Report [Summary + TOC]) @ https://www.emergenresearch.com/request-sample/27
The cell and gene therapy market is expected to grow rapidly in the coming years, driven by the increasing number of clinical trials underway, the commercial success of some early products, and the growing investment by biopharma companies in CGT research and development.
The number of cell and gene therapy clinical trials has increased rapidly in recent years, from just over 100 in 2012 to more than 1,200 in 2018. This increase is a result of the growing body of evidence supporting the efficacy of CGT, as well as the increasing investment by biopharma companies in this area.
The commercial success of some early cell and gene therapy products has also been a key driver of market growth. Novartis’s CAR-T therapy Kymriah was the first CGT product to be approved by the US Food and Drug Administration (FDA), and it has been a commercial success, with sales of over $1 billion in 2019.
Other cell and gene therapy products have also been approved in recent years, including Gilead’s Yescarta and Novartis’s Zolgensma. These approvals are significant because they provide proof-of-concept that CGT can be an effective treatment for a range of diseases.
The increasing investment by biopharma companies in CGT research and development is also a key driver of market growth. In 2018, global investment in CGT reached $11.8 billion, up from $5.6 billion in 2015.
This increase is due to the growing recognition of the potential of CGT, as well as the increasing number of clinical trials underway. In addition, many biopharma companies are establishing dedicated CGT divisions and making acquisitions in this area.
Cell and gene therapy is one of the advanced treatment methods used for treating cancer, cardiovascular diseases, central nervous system disorders, infectious diseases, and other chronic ailments. Moreover, it is considered as an effective alternative to conventional methods such as chemotherapy and radiation therapy.
Cell and Gene Therapy refers to the process of using living cells to treat or cure a disease. This therapy is still in its early stages of development, but has shown promise in treating a number of diseases, including cancer, heart disease, and genetic disorders.
Browse Full Report Description + Research Methodology + Table of Content + Infographics@ https://www.emergenresearch.com/industry-report/cell-and-gene-therapy-market
Some Key Highlights from the Report
- By application, the cancer segment is anticipated to grow at the fastest rate over the forecast period. The increasing prevalence of cancer is one of the major factors driving the segment growth. For instance, according to the World Health Organization, in 2018, there were 18.1 million new cases and 9.6 million cancer deaths worldwide. Moreover, favorable government initiatives are further fuelling the segment growth. In September 2019, President Donald Trump signed an executive order that would provide USD 500 million to support cancer research and cancer treatment over the next five years.
- On the basis of end user, the hospitals & clinics segment is expected to hold a significant market share over the forecast period. The segment growth is majorly attributed to the increasing preference for cell and gene therapy among patients. Moreover, hospitals & clinics are well-equipped with the latest technology and skilled personnel, which further promotes the segment growth.
- The stem cell therapy segment is expected to grow at the highest CAGR during the forecast period due to the increasing use of stem cells in the treatment of cancer and other chronic diseases. Also, the increasing investments by public and private organizations are propelling the growth of the cell therapy market.
- The oncology segment is expected to be the largest contributor to the market during the forecast period due to the increasing incidence of cancer, government support, and the availability of reimbursement policies.
- The CAR-T cell therapy segment is expected to grow at the highest CAGR during the forecast period due to the growing demand for personalized medicine and the increasing investments by public and private organizations.
- North America is expected to be the largest market for cell and gene therapy during the forecast period due to the availability of infrastructure and government support and the presence of key players in the region. Also, the increasing incidents of cancer are propelling the growth of the market in this region.
- Asia Pacific is expected to grow at the highest CAGR in the cell and gene therapy market during the forecast period due to the increasing prevalence of cancer, rising healthcare expenditure, and growing awareness about cell and gene therapy.
Emergen Research is Offering Limited Time Discount (Grab a Copy at Discounted Price Now) @ https://www.emergenresearch.com/request-discount/27
Emergen Research has segmented the global Cell and Gene Therapy Market on the basis of indication, vector type, and region:
Indication Outlook (Revenue, USD Billion; 2017-2027)
- Acute Lymphoblastic Leukemia (ALL)
- Inherited Retinal Disease
- Large B-Cell Lymphoma
- ADA-SCID
- Others
Vector Outlook (Revenue, USD Billion; 2017-2027)
- Lentivirus
- AAV
- Retrovirus & Gammaretrovirus
- Modified Herpes Simplex Virus
- Adenovirus
- Non-Viral Plasmid Vector
Regional Outlook (Revenue, USD Billion; 2017-2027)
- North America
- US.
- Canada
- Europe
- Germany
- UK
- France
- BENELUX
- Rest of Europe
- Asia Pacific
- China
- Japan
- South Korea
- Rest of APAC
- Latin America
- Brazil
- Rest of LATAM
- MEA
- Saudi Arabia
- UAE
- Rest of MEA
Custom Requirements can be requested for this Report [Customization Available] @ https://www.emergenresearch.com/request-for-customization/27
Explore More Reports Emergen Research:
Plant-Based Food & Beverage Alternatives Market
Fermented Food and Ingredients Market
Autonomous Delivery Vehicles Market
About Emergen Research
Emergen Research is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyze consumer behavior shifts across demographics, across industries, and help clients make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, Touch Points, Chemicals, Types, and Energy. We consistently update our research offerings to ensure our clients are aware of the latest trend’s existent in the market. Emergen Research has a strong base of experienced analysts from varied areas of expertise. Our industry experience and ability to develop a concrete solution to any research problems provides our clients with the ability to secure an edge over their respective competitors.
Contact Us:
Eric Lee
Corporate Sales Specialist
14671 110 Avenue, Surrey, British Columbia, V3R2A9
Emergen Research | Web: www.emergenresearch.com
Direct Line: +1 (604) 757-9756
E-mail: sales@emergenresearch.com
Emergen Research Media Citations: https://www.emergenresearch.com/media-citations
Press Release: https://www.emergenresearch.com/press-release/global-cell-and-gene-therapy-market
Blog article: https://www.emergenresearch.com/blog/top-10-leading-companies-in-cell-and-gene-therapy-market
Visit for More Insights: https://www.emergenresearch.com/insights
Explore Our Custom Intelligence services | Growth Consulting Services
Latest Published Titles Smart Cities Market | Smart Learning Market
Trending Titles Humanoid Robot Market | Incident Response Market